Innoviva Change in Assets/Liabilities 2010-2025 | INVA
Innoviva change in assets/liabilities from 2010 to 2025. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities
Innoviva Annual Change in Assets/Liabilities
(Millions of US $) |
| 2024 |
$-34 |
| 2023 |
$-11 |
| 2022 |
$-12 |
| 2021 |
$-17 |
| 2020 |
$-15 |
| 2019 |
$4 |
| 2018 |
$-13 |
| 2017 |
$-27 |
| 2016 |
$-21 |
| 2015 |
$-17 |
| 2014 |
$-25 |
| 2013 |
$0 |
| 2012 |
$-132 |
| 2011 |
$-14 |
| 2010 |
$-20 |
| 2009 |
$7 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.288B |
$0.359B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
